Literature DB >> 22169531

Trisomy 21 and early brain development.

Tarik F Haydar1, Roger H Reeves.   

Abstract

Trisomy for human chromosome 21 (Hsa21) results in Down syndrome (DS). The finished human genome sequence provides a thorough catalog of the genetic elements whose altered dosage perturbs development and function in DS. However, understanding how small alterations in the steady state transcript levels for <2% of human genes can disrupt development and function of essentially every cell presents a more complicated problem. Mouse models that recapitulate specific aspects of DS have been used to identify changes in brain morphogenesis and function. Here we provide a few examples of how trisomy for specific genes affects the development of the cortex and cerebellum to illustrate how gene dosage effects might contribute to divergence between the trisomic and euploid brains.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22169531      PMCID: PMC3273608          DOI: 10.1016/j.tins.2011.11.001

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  122 in total

1.  The neuropsychology of Down syndrome: evidence for hippocampal dysfunction.

Authors:  Bruce F Pennington; Jennifer Moon; Jamie Edgin; Jennifer Stedron; Lynn Nadel
Journal:  Child Dev       Date:  2003 Jan-Feb

2.  The caudal ganglionic eminence is a source of distinct cortical and subcortical cell populations.

Authors:  Susana Nery; Gord Fishell; Joshua G Corbin
Journal:  Nat Neurosci       Date:  2002-12       Impact factor: 24.884

3.  Layer specification of transplanted interneurons in developing mouse neocortex.

Authors:  Helen Valcanis; Seong-Seng Tan
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

4.  Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

Authors:  Ahmad Salehi; Jean-Dominique Delcroix; Pavel V Belichenko; Ke Zhan; Chengbiao Wu; Janice S Valletta; Ryoko Takimoto-Kimura; Alexander M Kleschevnikov; Kumar Sambamurti; Peter P Chung; Weiming Xia; Angela Villar; William A Campbell; Laura Shapiro Kulnane; Ralph A Nixon; Bruce T Lamb; Charles J Epstein; Gorazd B Stokin; Lawrence S B Goldstein; William C Mobley
Journal:  Neuron       Date:  2006-07-06       Impact factor: 17.173

5.  Anomalous brain morphology on magnetic resonance images in Williams syndrome and Down syndrome.

Authors:  T L Jernigan; U Bellugi
Journal:  Arch Neurol       Date:  1990-05

6.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

7.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Wade Morishita; Elizabeth Zuniga; James Nguyen; Martina Blank; Robert C Malenka; Craig C Garner
Journal:  Nat Neurosci       Date:  2007-02-25       Impact factor: 24.884

Review 8.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

9.  Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome.

Authors:  Pascal Kahlem; Marc Sultan; Ralf Herwig; Matthias Steinfath; Daniela Balzereit; Barbara Eppens; Nidhi G Saran; Mathew T Pletcher; Sarah T South; Gail Stetten; Hans Lehrach; Roger H Reeves; Marie-Laure Yaspo
Journal:  Genome Res       Date:  2004-07       Impact factor: 9.043

10.  Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.

Authors:  Fayçal Guedj; Catherine Sébrié; Isabelle Rivals; Aurelie Ledru; Evelyne Paly; Jean C Bizot; Desmond Smith; Edward Rubin; Brigitte Gillet; Mariona Arbones; Jean M Delabar
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more
  78 in total

1.  DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.

Authors:  Nobuhiro Kurabayashi; Minh Dang Nguyen; Kamon Sanada
Journal:  EMBO Rep       Date:  2015-09-15       Impact factor: 8.807

2.  OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome.

Authors:  Ranjie Xu; Andrew T Brawner; Shenglan Li; Jing-Jing Liu; Hyosung Kim; Haipeng Xue; Zhiping P Pang; Woo-Yang Kim; Ronald P Hart; Ying Liu; Peng Jiang
Journal:  Cell Stem Cell       Date:  2019-05-23       Impact factor: 24.633

3.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

4.  Down syndrome is accompanied by significantly reduced cortical grey-white matter tissue contrast.

Authors:  Anke Bletsch; Caroline Mann; Derek S Andrews; Eileen Daly; Giles M Y Tan; Declan G M Murphy; Christine Ecker
Journal:  Hum Brain Mapp       Date:  2018-06-08       Impact factor: 5.038

Review 5.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

Review 6.  Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.

Authors:  Dimphna H Meijer; Michael F Kane; Shwetal Mehta; Hongye Liu; Emily Harrington; Christopher M Taylor; Charles D Stiles; David H Rowitch
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

7.  A quantitative transcriptome reference map of the normal human brain.

Authors:  Maria Caracausi; Lorenza Vitale; Maria Chiara Pelleri; Allison Piovesan; Samantha Bruno; Pierluigi Strippoli
Journal:  Neurogenetics       Date:  2014-09-04       Impact factor: 2.660

8.  Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.

Authors:  Jose Luis Olmos-Serrano; Hyo Jung Kang; William A Tyler; John C Silbereis; Feng Cheng; Ying Zhu; Mihovil Pletikos; Lucija Jankovic-Rapan; Nathan P Cramer; Zygmunt Galdzicki; Joseph Goodliffe; Alan Peters; Claire Sethares; Ivana Delalle; Jeffrey A Golden; Tarik F Haydar; Nenad Sestan
Journal:  Neuron       Date:  2016-02-25       Impact factor: 17.173

9.  DSCAM promotes refinement in the mouse retina through cell death and restriction of exploring dendrites.

Authors:  Shuai Li; Joshua M Sukeena; Aaron B Simmons; Ethan J Hansen; Renee E Nuhn; Ivy S Samuels; Peter G Fuerst
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

10.  A 'cure' for Down syndrome: what do parents want?

Authors:  A Inglis; Z Lohn; J C Austin; C Hippman
Journal:  Clin Genet       Date:  2014-03-21       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.